Treatment of Chronic Hepatitis C Virus Infection

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the webinars held October 19, 2016 and October 28, 2016. If you participated in the live webinars, you are not eligible for continuing education credits from this archive.

This activity is valid from December 15, 2016 to December 31, 2018

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

These presentations require Adobe Flash Player.  You can download it here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Merck & Company




Hepatitis is the inflammation of the liver. There are several types of HCV, genotype 1A is the most prevalent in the US, and it’s been the most difficult to treat and cure. There are approximately 3.2 million people in the US with chronic Hepatitis C (CHC) infection. There could be many more, as HCV infections usually show mild to no symptoms. The most prevalent population believed to be infected with the hepatitis C virus (HCV) were born from 1945 to 1965 and probably infected during the 1970’s and ‘80’s, and many of them still are undiagnosed due to the lack of symptoms. Fortunately for patients with hepatitis C, several new treatment options have become available, giving physicians individualized options with vastly increased cure rates.

This program on overcoming challenges in HCV management with novel therapies will take a close look at genotype 1 and 4 HCV, providing attendees with education that will assist them in developing the best strategy to improve outcomes for their Hepatitis C member population. Attendees will leave with ability to increase screening protocols for Hepatitis C, and understand treatment barriers and solutions for patient adherence, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.

Upon Completion of this activity, participants will be able to:

  • Review the efficacies, indications, & safety profiles of new and emerging direct-acting antiviral combinations in the management of HCV patients with genotype 1 or 4 infection

  • Integrate guideline recommendations and clinical data of emerging HCV treatments to optimize individualized care for genotype 1 or 4 patients

  • Assess factors that may lead to treatment failure in patients receiving direct-acting antiviral combinations

  • Identify and overcome patient- and provider-related barriers to optimal HCV management

Faculty: Mark Sulkowski, MD
Medical Director, Viral Hepatitis Center
Professor of Medicine, Johns Hopkins University


Dr. Sulkowski receives research funding related to HCV with funds paid to John Hopkins University, from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck. Dr. Sulkowski also serves as a scientific advisor to AbbVie, Achillion, Bristol-Myers Squibb, Cocrystal, Gilead, Janssen, and Merck.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This presentation is supported by an educational grant from Merck & Company

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.